DIL vs INDOUS: Stock Comparison
DIL shows lower leverage, while INDO US BIOTECH shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
DIL leads 3; INDOUS leads 5 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | DIL | INDOUS |
|---|---|---|
| Sector | Fast Moving Consumer Goods | Fast Moving Consumer Goods |
| Industry | Other Agricultural Products | Other Agricultural Products |
Price
| Metric | DIL | INDOUS |
|---|---|---|
| Live Price | ₹1.77 | ₹65.34 |
| Day Change | -2.21% | -1.85% |
| Volume | 2 L | 4,878 |
| 52-Week High | ₹2.1 | ₹159 |
| 52-Week Low | ₹1.62 | ₹57.5 |
| Distance from 52W High | -15.71% | -58.91% |
Valuation
| Metric | DIL | INDOUS |
|---|---|---|
| Market Cap | ₹0 Cr | ₹134 Cr |
| P/E Ratio | — | 0x |
| P/B Ratio | — | 0x |
| EPS | ₹-0.01 | ₹1,69,098.66 |
| Book Value | ₹11.9 | ₹63.54 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | DIL | INDOUS |
|---|---|---|
| Revenue Growth (TTM YoY) | -99.01% | -22% |
| EPS Growth (TTM YoY) | 0% | -47.3% |
| Qtr Sales Growth | — | 0% |
| Qtr Profit Growth | 99.21% | 0% |
Profitability & Leverage
| Metric | DIL | INDOUS |
|---|---|---|
| ROE | -12.64% | 14.18% |
| ROCE | -12.34% | 10.86% |
| Net Margin | 10.61% | 11.88% |
| Operating Margin | — | 14.64% |
| Debt to Equity | 0.02x | 0.4x |
Shareholding
As of Mar 2025 • change vs previous quarter| Metric | DIL | INDOUS |
|---|---|---|
| Promoter Holding | 9.41% | 68.29% |
| FII Holding | 0% | 0.01% |
| DII Holding | 0% | 0.25%▲ 0.25 pp |
| Public Holding | 90.59% | 31.45%▼ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DIL and INDO US BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.